US 12,276,663 B2
Detection of human leukocyte antigen-A*32:01 in connection with determining drug reaction with eosinophilia and systemic symptoms (DRESS) and methods of treating bacterial infection in a subject with vancomycin-induced DRESS
Elizabeth Phillips, Nashville, TN (US); Simon Mallal, Nashville, TN (US); Katherine Konvinse, Nashville, TN (US); and Abha Chopra, Nashville, TN (US)
Assigned to Vanderbilt University, Nashville, TN (US)
Appl. No. 17/427,887
Filed by VANDERBILT UNIVERSITY, Nashville, TN (US)
PCT Filed Feb. 14, 2020, PCT No. PCT/US2020/018420
§ 371(c)(1), (2) Date Aug. 2, 2021,
PCT Pub. No. WO2020/168282, PCT Pub. Date Aug. 20, 2020.
Claims priority of provisional application 62/805,717, filed on Feb. 14, 2019.
Prior Publication US 2022/0107316 A1, Apr. 7, 2022
Int. Cl. G01N 33/569 (2006.01)
CPC G01N 33/56977 (2013.01) [G01N 2333/70539 (2013.01); G01N 2800/24 (2013.01)] 19 Claims
 
1. A method of detecting a human leukocyte antigen (HLA)-A*32:01 allele in a subject, comprising:
(a) obtaining a biological sample from the subject;
(b) detecting whether HLA-A*32:01 is present in the sample using a primer specific for a HLA-A*32 allele to determine whether the subject is at risk for developing or has vancomycin-induced drug reaction with eosinophilia and systemic symptoms (DRESS) when HLA-A*32:01 is present in the sample, wherein the primer specific for HLA-A*32 is HLA 32-88F (SEQ ID NO: 1).